The estimated Net Worth of Alexander Azoy is at least 72 千$ dollars as of 13 August 2024. Mr Azoy owns over 1,357 units of Unity Biotechnology Inc stock worth over 26,698$ and over the last 6 years he sold UBX stock worth over 45,308$.
Mr has made over 3 trades of the Unity Biotechnology Inc stock since 2023, according to the Form 4 filled with the SEC. Most recently he sold 1,357 units of UBX stock worth 20,314$ on 13 August 2024.
The largest trade he's ever made was selling 1,357 units of Unity Biotechnology Inc stock on 13 August 2024 worth over 20,314$. On average, Mr trades about 242 units every 37 days since 2019. As of 13 August 2024 he still owns at least 19,070 units of Unity Biotechnology Inc stock.
You can see the complete history of Mr Azoy stock trades at the bottom of the page.
Alexander Azoy is the VP of Fin., Chief Accounting Officer, Controller & Principal Accounting Officer at Unity Biotechnology Inc.
Mr Azoy is 45, he's been the VP of Fin.、 Chief Accounting Officer、 Controller & Principal Accounting Officer of Unity Biotechnology Inc since . There are 22 older and no younger executives at Unity Biotechnology Inc. The oldest executive at Unity Biotechnology Inc is David Lacey, 67, who is the Independent Director.
Alexander's mailing address filed with the SEC is C/O ARCUS BIOSCIENCES, INC., 3928 POINT EDEN WAY, HAYWARD, CA, 94545.
Over the last 7 years, insiders at Unity Biotechnology Inc have traded over 9,012,473$ worth of Unity Biotechnology Inc stock and bought 3,200 units worth 28,480$ . The most active insiders traders include Kristina Burow、Robert Nelsen、Nathaniel E David. On average, Unity Biotechnology Inc executives and independent directors trade stock every 54 days with the average trade being worth of 65,316$. The most recent stock trade was executed by Alexander Hieu Nguyen on 2 August 2024, trading 154 units of UBX stock currently worth 236$.
unity biotechnology is developing therapeutics to extend healthspan by slowing, halting or reversing diseases of aging. unity's initial focus is on creating senolytic medicines to selectively eliminate senescent cells and thereby treat age-related diseases, such as osteoarthritis, eye diseases and pulmonary diseases. more information is available at www.unitybiotechnology.com.
Unity Biotechnology Inc executives and other stock owners filed with the SEC include: